<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097145</url>
  </required_header>
  <id_info>
    <org_study_id>2019-07</org_study_id>
    <nct_id>NCT04097145</nct_id>
  </id_info>
  <brief_title>Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial</brief_title>
  <acronym>CLASP II TR</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System
      in patients with symptomatic severe tricuspid regurgitation who have been determined to be at
      an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the
      cardiac surgeon with concurrence by the local Heart Team
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and
      effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter
      Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with
      tricuspid regurgitation. Patients will be seen for follow-up visits at discharge, 30 days, 3
      months, 6 months, and annually through 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical composite endpoint of various adverse events and improvement in quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of a composite of adverse events including mortality, heart failure hospitalization, need for surgery on the tricuspid valve, and improvement of quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of various adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Rates of various adverse events at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in TR grade</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months, annual for 5 years</time_frame>
    <description>Number of patients with reduction in TR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status - KCCQ</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years</time_frame>
    <description>Number of points of improvement in health status as measured by Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status - SF-36</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years</time_frame>
    <description>Number of points of improvement in health status as measured by 36 item short form survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-Minute Walk Test</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years</time_frame>
    <description>Change in distance (m) from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">825</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Tricuspid Valve Disease</condition>
  <arm_group>
    <arm_group_label>Edwards PASCAL System &amp; OMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy (OMT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards PASCAL System</intervention_name>
    <description>Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy</description>
    <arm_group_label>Edwards PASCAL System &amp; OMT</arm_group_label>
    <other_name>Transcatheter tricuspid valve repair (TTVr)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Optimal Medical Therapy alone in patients with tricuspid regurgitation</description>
    <arm_group_label>Optimal Medical Therapy (OMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eighteen (18) years of age or older

          -  Patient is deemed symptomatic despite medical therapy and confirmed by the local Heart
             Team

          -  Severe or greater tricuspid regurgitation

          -  New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the
             prior 12 months

          -  Patient is at an intermediate or greater estimated risk of mortality with tricuspid
             valve surgery as determined by the cardiac surgeon with concurrence by the local Heart
             Team

          -  Patient is able and willing to give informed consent, follow protocol procedures, and
             comply with follow-up visit requirements

        Exclusion Criteria:

          -  Tricuspid valve anatomy not evaluable by TTE and TEE

          -  Tricuspid valve anatomy precludes proper device deployment and function

          -  Patient with refractory heart failure requiring advanced intervention (i.e. left
             ventricular assist device, transplantation) (ACC/AHA Stage D heart failure)

          -  Primary non-degenerative tricuspid disease

          -  Previous tricuspid valve repair or replacement that would interfere with placement of
             PASCAL

          -  Clinically significant, untreated coronary artery disease

          -  Recent Stroke

          -  Other severe valve disorders requiring intervention

          -  Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months

          -  Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation

          -  Active endocarditis

          -  Continuous home oxygen for primary severe COPD

          -  Pregnant or planning pregnancy within the next 12 months. Note: Female patients of
             childbearing potential need to have a negative pregnancy test performed within 14 days
             prior to intervention and be adherent to an accepted method of contraception

          -  Concurrent medical condition with a life expectancy of less than 12 months in the
             judgment of the Investigator

          -  Patient is currently participating in another investigational biologic, drug or device
             clinical study where the primary study endpoint was not reached at time of enrollment

          -  Other medical, social, or psychological conditions that preclude appropriate consent
             and follow-up, including patients under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edwards TMTT Clinical Affairs</last_name>
    <phone>(949) 250-2500</phone>
    <email>TMTT_Clinical@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elle McCloskey, RN</last_name>
      <phone>312-926-0840</phone>
      <email>elizabeth.mccloskey@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Christina Arroyo</last_name>
      <phone>312-926-7078</phone>
      <email>christina.arroyo@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. Chris Malaisrie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jyothy Puthumana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital, Northwell Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Cameron</last_name>
      <phone>503-418-9677</phone>
      <email>cameronk@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zoe Kilmer</last_name>
      <phone>503-494-3491</phone>
      <email>kilmer@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Firas Zahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Chadderdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Song, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Steiner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katerine Rajotte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Khouw</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Cardiovascular Institute/UPMC Pinnacle</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCA Houston Healthcare Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White - The Heart Hospital - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Velder</last_name>
      <phone>469-814-4732</phone>
      <email>Gabriella.Velder@bswhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Necole Kell</last_name>
      <phone>469-814-4871</phone>
      <email>Necole.Kell@bswhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert L. Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Molly Szerlip, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Grayburn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Al-Azizi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Sayfo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

